Mon, Dec 22, 2014, 12:21 AM EST - U.S. Markets open in 9 hrs 9 mins

Recent

% | $
Quotes you view appear here for quick access.

Northwest Biotherapeutics, Inc. Message Board

  • anotherday1225 anotherday1225 Mar 7, 2013 11:49 AM Flag

    Like the clarity, but...

    was it really necessary to name competitors and provide a comparison of enrollment speed? Pretty easy to hand-pick examples where you are faster.. probably numerous others not mentioned going the other way. Just let the company's progress stand, and leave other companies out of it. All in, glad to see this transparency...

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It is so tedious with this company. They announce a trial completion schedule and then throw in a disclaimer in case they miss the target. Rather than back up their schedule with current accrual numbers so investors can judge how believable it all is they compare their claims with accruals of trials by other companies. Who cares about that? Then, like clockwork, they trot out the prostate phase III as something that is supposed to have meaning. They have done nothing on that in over 10 years. The patent is going to expire in 2 years. After settling with Lonza and destroying everything related to that trial it will probably take at least that long to initiate a phase III trial. Likely they will have to do at least a small phase II before the phase III can start because of Lonza. So, there is really no value there. A company interested in picking that up does not need NWBO. It would be much better if this company didn't constantly try to be evasive.

    • My guess is that they were faced with this question - with the competitors named - during their interactions with investors. And that is probbaly why it became necessary to put things in perspective, with the names mnetioned. Nothing derogatory, just stating facts as they are. Especially on an issue where there is much attention and talk and perhaps an equal amount of confusion (you would recall how many times some people even on this board have used enrollment to bash NWBO).

      As I've said in another post, the importance of a thorough screening and enrollment process can simply not be over-emphasized in a Phase III trial. This takes time, especially on a large trial in two continents. But, the clariy offered helps go a long way in clearing the air on this issue.

      Sentiment: Strong Buy

    • you are missing the point

 
NWBO
5.74+0.050(+0.88%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.